Overall, multiple factors are associated with increased risk or accelerated progression to CFRD, such as age, gender, CFTR genotype, genetic modifiers, the degree of pancreatic exocrine deficiency, lung function, liver disease, inflammation, the presence of β-cell specific autoantibodies, etc. Defining how the combination of these factors drives the progression to CFRD in each individual would increase our understanding of the heterogeneity of disease severity and onset. This evidence concerns the gene CFTR and liver disorder.